TENUATE DOSPAN Drug Patent Profile

When do Tenuate Dospan patents expire, and when can generic versions of Tenuate Dospan launch?

Tenuate Dospan is a drug marketed by Ani Pharms and is included in one NDA.

The generic ingredient in TENUATE DOSPAN is diethylpropion hydrochloride. There is one drug master file entry for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the diethylpropion hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tenuate Dospan

A generic version of TENUATE DOSPAN was approved as diethylpropion hydrochloride by AVANTHI INC on December 22^nd, 2010.

Summary for TENUATE DOSPAN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	38
Patent Applications:	787
DailyMed Link:	TENUATE DOSPAN at DailyMed

US Patents and Regulatory Information for TENUATE DOSPAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ani Pharms	TENUATE DOSPAN	diethylpropion hydrochloride	TABLET, EXTENDED RELEASE;ORAL	012546-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Tenuate Dospan Market Dynamics and Financial Trajectory

Last updated: August 6, 2026

Tenuate Dospan, the extended-release formulation of diethylpropion hydrochloride, is a mature Schedule IV anorectic with limited commercial value. Its market position has weakened because of generic substitution, low-cost alternatives, short treatment duration, controlled-substance restrictions, and competition from newer anti-obesity medicines. No publicly listed manufacturer reports standalone Tenuate Dospan revenue, so the product’s financial trajectory must be assessed through regulatory status, prescription economics, competitive displacement, and manufacturing access rather than reported brand sales.

What is Tenuate Dospan and how is it used?

Tenuate Dospan contains diethylpropion hydrochloride 75 mg in an extended-release tablet. It is indicated as a short-term adjunct to calorie restriction and behavioral modification for patients with an initial body-mass index of at least 30 kg/m² who have not responded adequately to diet and exercise alone.[1]

The product is a sympathomimetic amine with pharmacologic similarities to amphetamine-class stimulants. The FDA label limits use to short-term therapy, generally interpreted as a few weeks rather than chronic treatment.[1]

Attribute	Tenuate Dospan
Active ingredient	Diethylpropion hydrochloride
Dosage form	Extended-release oral tablet
Strength	75 mg
Therapeutic area	Obesity and weight management
FDA-controlled status	Schedule IV
Typical dosing	One extended-release tablet daily, generally mid-morning
Treatment duration	Short term
Original commercial category	Prescription anorectic
Current competitive position	Mature, low-growth, generic-exposed product

The extended-release formulation was designed to provide once-daily administration compared with immediate-release diethylpropion tablets, which are generally administered several times per day.[1]

When did Tenuate Dospan lose exclusivity?

Tenuate Dospan has no meaningful remaining exclusivity based on the age of diethylpropion, the long-established regulatory history of the product, and the availability of generic diethylpropion products. Its commercial economics are therefore governed primarily by generic competition rather than patent protection.

Exclusivity category	Current assessment
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No current protection identified
Regulatory exclusivity	Expired
Composition-of-matter patent	No commercially relevant term remains
Formulation patent	No currently material exclusivity identified
Method-of-use patent	No currently material exclusivity identified
Generic competition	Present or historically available
Current economic moat	Manufacturing, distribution, supply continuity, and controlled-substance compliance

The product’s patent position differs from newer obesity drugs. Tenuate Dospan does not have a modern franchise built around multiple later-expiring formulation, device, combination, or method-of-use patents. Its commercial life is consistent with an older small-molecule product whose exclusivity period ended decades ago.

What is the FDA regulatory status of Tenuate Dospan?

Tenuate Dospan remains associated with an FDA-approved diethylpropion extended-release product, but commercial availability and labeler status can change independently of the underlying approval. FDA product databases distinguish between approved, marketed, and discontinued products. A product may retain an approval record even when a particular manufacturer no longer sells it.[2]

The regulatory characteristics that affect market access are:

1. Diethylpropion is a Schedule IV controlled substance.
2. The FDA-approved use is short term.
3. The product is indicated only as an adjunct to diet and behavioral modification.
4. The label carries stimulant-related warnings and contraindications.
5. Prescribing is constrained by abuse, misuse, dependence, cardiovascular, and psychiatric risk considerations.[1]

These restrictions reduce the probability that Tenuate Dospan will become a high-volume chronic obesity product. They also limit the product’s ability to compete directly with long-term therapies such as GLP-1 and dual incretin medicines.

What is the Orange Book status of Tenuate Dospan?

The relevant Orange Book question is whether an active patent or regulatory exclusivity period blocks an abbreviated new drug application. For a legacy diethylpropion product, the commercial answer is no meaningful Orange Book barrier.

The product’s principal exposure is generic competition. A potential generic applicant would generally evaluate:

• Bioequivalence for the extended-release dosage form.
• Controlled-substance registration and quota requirements.
• Manufacturing of the modified-release matrix or delivery system.
• Label conformity.
• Stability and dissolution performance.
• Distribution controls and anti-diversion procedures.

No material current Orange Book patent estate is associated with the old active ingredient that would support a branded delay to generic entry. The principal competitive barrier is operational rather than legal.

How many patents cover Tenuate Dospan?

Tenuate Dospan does not appear to have a commercially significant live patent estate. The relevant protection categories are effectively exhausted.

Patent category	Strategic value today
Diethylpropion molecule	None from a current exclusivity perspective
Extended-release formulation	Limited unless a separate enforceable patent is identified
Tablet manufacturing process	Potentially useful as know-how, but not a broad market barrier
Method of treating obesity	Weak commercial value because the approved use is old
Combination therapy	No established Tenuate Dospan franchise
Device or delivery platform	Not applicable to the marketed tablet

A company could still hold confidential manufacturing know-how, supplier relationships, validated dissolution specifications, or regulatory documentation. Those assets may support supply reliability but do not create market exclusivity equivalent to a valid patent.

Which companies are challenging or competing with Tenuate Dospan?

The competitive set includes generic diethylpropion manufacturers, older sympathomimetic anorectics, and newer chronic weight-management therapies.

Direct generic competition

Generic diethylpropion products compete on:

• Price.
• Pharmacy stocking.
• Wholesaler availability.
• Controlled-substance compliance.
• Consistent supply.
• Extended-release product quality.

The generic market is fragmented and relatively low value. Manufacturers generally have limited ability to raise price without attracting substitution or losing formulary and pharmacy access.

Older branded and generic anorectics

Tenuate Dospan competes with phentermine products and, in some prescribing settings, phentermine/topiramate extended-release. Phentermine has broader market recognition and a larger generic supply base. Both products face short-term-use limitations, but phentermine has stronger prescribing visibility in the U.S. obesity market.

Newer chronic therapies

The main strategic threat comes from semaglutide, tirzepatide, liraglutide, and related metabolic therapies. These products have:

• Chronic-use labeling in relevant indications.
• Larger clinical-development programs.
• Greater efficacy in average weight reduction.
• Broader cardiometabolic positioning.
• Higher reimbursement and pricing potential.
• Stronger manufacturer investment and patient-support infrastructure.

Tenuate Dospan retains a low-cost role for selected patients, but it does not compete on clinical efficacy, durability of weight loss, or manufacturer resources.

How does Tenuate Dospan compare with newer obesity drugs?

Factor	Tenuate Dospan	Semaglutide or tirzepatide obesity products
Mechanism	Sympathomimetic anorectic	Incretin-based therapy
Route	Oral tablet	Injectable
FDA use	Short term	Chronic weight management in labeled populations
Controlled substance	Yes, Schedule IV	No
Typical price structure	Low-cost generic or legacy product	High-cost branded therapy
Weight-loss efficacy	Lower	Substantially higher in pivotal trials
Supply constraints	Manufacturing and controlled-substance supply	Drug-device and active pharmaceutical ingredient capacity
Patent position	Minimal remaining protection	Significant active patent and regulatory estates
Revenue potential	Low	High
Commercial growth	Declining or flat	Expanding, subject to access and competition

The products are not economically interchangeable. Tenuate Dospan competes primarily as a low-cost, short-duration option. Newer incretin therapies compete as high-value chronic disease treatments with large reimbursement and investment markets.

What generic entry risks exist for Tenuate Dospan?

Generic entry is no longer an emerging risk. It is the product’s existing market structure. The relevant risks are further price compression, supplier exits, and channel substitution.

A generic manufacturer does not need to overcome a substantial branded patent barrier. Its main technical challenge is demonstrating bioequivalence for the extended-release formulation. FDA approval may require evidence that the release profile is sufficiently comparable to the reference product under applicable product-specific guidance.[3]

The most important commercial risks are:

• Additional generic entrants reducing unit economics.
• Manufacturer discontinuation caused by low margins.
• Controlled-substance quota limitations.
• Wholesaler or pharmacy reluctance to stock low-volume products.
• Regulatory scrutiny of stimulant prescribing.
• Substitution by phentermine or newer anti-obesity drugs.
• Demand migration to chronic GLP-1-based therapy.

These risks can produce intermittent shortages even when legal entry is easy. Low-margin controlled substances can become vulnerable when only one or two manufacturers remain active.

What formulation patents protect Tenuate Dospan?

The commercial value of the Dospan formulation came from extended release rather than from a new active ingredient. Any historical formulation protection would have focused on release kinetics, excipients, tablet structure, or manufacturing methods. Those protections are not expected to provide current market exclusivity for the mature product.

The formulation still has technical importance. A manufacturer must control:

• Drug-release rate.
• Tablet hardness and coating.
• Dissolution across pH conditions.
• Dose uniformity.
• Stability during storage.
• Manufacturing reproducibility.

These characteristics can create practical barriers for a new supplier even when they do not support a patent-based barrier. A technically difficult extended-release product may have fewer active suppliers than its patent status suggests.

What patent litigation affects Tenuate Dospan?

No major current patent litigation involving Tenuate Dospan is a central market factor. The product’s age and generic status make Paragraph IV litigation unlikely to influence valuation or launch timing.

For newer obesity products, Paragraph IV litigation is a major commercial issue because generic applicants challenge listed patents before patent expiration. Tenuate Dospan is different. Its important exclusivity dates have passed, and the product lacks the high-value patent cluster seen in newer obesity franchises.

The more relevant legal issues are controlled-substance compliance, product liability, prescribing practices, advertising restrictions, and potential regulatory action involving stimulant weight-loss medicines.

Does Tenuate Dospan have biosimilar risk?

No. Tenuate Dospan is a synthetic small-molecule tablet, not a biologic. Biosimilar regulation under the Public Health Service Act does not apply. Competitive entry occurs through the generic drug pathway under an abbreviated new drug application.

This distinction matters commercially. Tenuate Dospan does not face biosimilar interchangeability, biologic reference-product erosion, or biologics patent litigation. Its exposure is conventional generic substitution.

What is the financial trajectory of Tenuate Dospan?

Tenuate Dospan has a low and declining financial profile relative to modern obesity drugs. No major manufacturer publicly reports standalone Tenuate Dospan revenue, operating profit, or product-level guidance. The product is generally too small and too mature to appear as a separately disclosed reporting segment.

Revenue drivers

Revenue is constrained by:

• Generic price competition.
• Short treatment duration.
• Low-cost alternatives.
• Limited insurance coverage for obesity medicines.
• Controlled-substance prescribing restrictions.
• Weak brand recognition compared with phentermine.
• Substitution by newer chronic therapies.

Cost structure

The tablet itself is inexpensive to manufacture relative to injectable biologics. Costs are concentrated in:

• Active pharmaceutical ingredient sourcing.
• Controlled-substance compliance.
• Quality testing.
• Extended-release manufacturing.
• Regulatory maintenance.
• Distribution controls.
• Inventory and shortage management.

The low manufacturing cost does not guarantee high profitability. Low volume and price competition can make regulatory and supply-chain overhead material on a per-unit basis.

Financial outlook

Period	Expected market direction
Historical	Decline from branded product to generic or limited-labeler economics
Near term	Flat to declining demand, with supply volatility possible
Medium term	Further erosion from chronic incretin therapies
Long term	Niche product with residual demand among price-sensitive or stimulant-preferring patients

The strongest potential for value is not a conventional growth trajectory. It lies in reliable supply, low-cost manufacturing, contract manufacturing, or portfolio bundling with other generic controlled substances. A buyer would likely value the product for cash-flow persistence or channel access rather than for patent-backed expansion.

What licensing deals affect Tenuate Dospan?

No major recent licensing transaction has established Tenuate Dospan as a strategic growth asset. Historical rights may have moved among pharmaceutical companies as older anorectic portfolios changed ownership, but the product does not have the licensing profile of a patented obesity medicine, proprietary delivery platform, or biologic.

Potential transaction value would depend on:

• Current FDA marketing status.
• Active manufacturer and supply agreements.
• Historical sales volume.
• Controlled-substance registrations.
• Manufacturing site qualification.
• Product-specific regulatory files.
• Liability allocation.
• Wholesale and pharmacy distribution.

Without standalone revenue disclosure, valuation would require transaction-level operating data rather than public-company financial statements.

What generic launch scenarios exist for Tenuate Dospan?

A new generic launch would not normally require a branded patent settlement. The main launch scenarios are operational:

1. An additional supplier enters and drives price erosion.
2. An incumbent exits, allowing temporary price recovery.
3. A shortage creates short-term demand for an available supplier.
4. Pharmacies substitute between immediate-release and extended-release diethylpropion where clinically and legally appropriate.
5. Prescribers shift patients to phentermine or chronic incretin therapies.

The most plausible long-term scenario is continued niche use with intermittent supplier concentration. A rapid return to broad obesity-market growth is unlikely.

What geographic markets remain relevant?

The United States is the most commercially relevant market because of the product’s established FDA history and controlled-substance framework. International opportunities are limited by differing approvals, stimulant controls, obesity-treatment guidelines, and reimbursement systems.

Geographic expansion would face:

• Country-specific registration requirements.
• Controlled-drug scheduling differences.
• Local safety restrictions.
• Limited payer interest in short-term anorectics.
• Generic pricing pressure.
• Competition from locally established appetite suppressants.

The product is better suited to a focused U.S. generic or legacy-brand strategy than to a multinational expansion plan.

Key Takeaways

• Tenuate Dospan is an extended-release diethylpropion tablet for short-term obesity treatment.
• Its original exclusivity has expired, and no commercially meaningful current patent estate is apparent.
• The product competes in a mature generic market rather than a branded innovation market.
• Its Schedule IV status and short-term label limit chronic prescription growth.
• Generic competition is an existing condition, not a future threat.
• Newer semaglutide- and tirzepatide-based therapies are the principal long-term demand substitute.
• No major current patent litigation, Paragraph IV settlement, biosimilar risk, or licensing transaction drives the product’s outlook.
• Standalone revenue is not publicly disclosed; financial analysis must rely on market structure and supply economics.
• The likely trajectory is flat to declining revenue with possible episodic supply-driven pricing.

FAQs About Tenuate Dospan

Is Tenuate Dospan still commercially available?

Availability depends on the active manufacturer, wholesaler inventory, and pharmacy supply. FDA approval records and commercial marketing status are separate issues, so an approved product may not be consistently stocked.

Is diethylpropion ER the same as Tenuate Dospan?

Diethylpropion extended-release tablets are the generic equivalent category associated with Tenuate Dospan. Product-specific labeling, strength, manufacturer, and availability must be confirmed in the FDA and pharmacy databases.

Can Tenuate Dospan become a high-growth obesity product?

A high-growth trajectory is unlikely because the product is short-term, controlled, generic-exposed, and clinically outperformed by chronic incretin therapies in the modern obesity market.

Does Tenuate Dospan require a Paragraph IV patent challenge?

Normally no. A Paragraph IV certification is relevant when an ANDA applicant challenges listed patents. Tenuate Dospan does not have a commercially material patent barrier that is expected to control generic entry.

What is the main investment risk for a Tenuate Dospan manufacturer?

The main risk is margin compression combined with low volume and supply obligations. A manufacturer may retain demand but lack sufficient pricing power to justify the compliance, quality, and controlled-substance distribution costs.

References

1. U.S. Food and Drug Administration. (n.d.). Tenuate Dospan (diethylpropion hydrochloride) extended-release tablet prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database.
3. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations.